{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:10:38Z","timestamp":1795133438800,"version":"4.10.3"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"7996","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2024,1,25]]},"DOI":"10.1038\/s41586-023-06903-x","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T17:09:58Z","timestamp":1702314598000},"page":"778-787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling"],"prefix":"10.1038","volume":"625","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-702X","authenticated-orcid":false,"given":"Stefan K.","family":"Alig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Shahrokh Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Flerlage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie E.","family":"Flerlage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragini","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Binkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navika","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8le","family":"Telenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurik A.","family":"Mutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4128-2537","authenticated-orcid":false,"given":"Joseph G.","family":"Schroers-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Sworder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6451-712X","authenticated-orcid":false,"given":"Daniel A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7196-1621","authenticated-orcid":false,"given":"Jan","family":"B\u00f6geholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6946-8256","authenticated-orcid":false,"given":"Shengqin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan R.","family":"Kathuria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6577-5427","authenticated-orcid":false,"given":"Chih Long","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya J.","family":"Strohband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0941-5360","authenticated-orcid":false,"given":"Deanna","family":"Langfitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine Faye","family":"Pobre-Piza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri","family":"Surman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2657-5158","authenticated-orcid":false,"given":"Feng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0397-1086","authenticated-orcid":false,"given":"Thomas","family":"Tousseyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieselot","family":"Buedts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0125-0194","authenticated-orcid":false,"given":"Richard","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-1018","authenticated-orcid":false,"given":"Yasodha","family":"Natkunam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc-Matthieu","family":"Fornecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6382-4651","authenticated-orcid":false,"given":"David M.","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianna J.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4719-1935","authenticated-orcid":false,"given":"Peter","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-9750","authenticated-orcid":false,"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2032-0581","authenticated-orcid":false,"given":"Maximilian","family":"Diehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-5625","authenticated-orcid":false,"given":"Ash A.","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"6903_CR1","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.medj.2021.09.002","volume":"2","author":"S Sobesky","year":"2021","unstructured":"Sobesky, S. et al. In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin\u2019s lymphoma and facilitates ultrasensitive residual disease detection. Med 2, 1171\u20131193.e11 (2021).","journal-title":"Med"},{"key":"6903_CR2","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","volume":"131","author":"V Spina","year":"2018","unstructured":"Spina, V. et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 131, 2413\u20132425 (2018).","journal-title":"Blood"},{"key":"6903_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41375-019-0541-6","volume":"34","author":"AK Desch","year":"2020","unstructured":"Desch, A. K. et al. Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia 34, 151\u2013166 (2020).","journal-title":"Leukemia"},{"key":"6903_CR4","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2352-3026(14)00039-8","volume":"2","author":"P Vandenberghe","year":"2015","unstructured":"Vandenberghe, P. et al. Non-invasive detection of genomic imbalances in Hodgkin\/Reed\u2013Sternberg cells in early and advanced stage Hodgkin\u2019s lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol. 2, e55\u2013e65 (2015).","journal-title":"Lancet Haematol."},{"key":"6903_CR5","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","volume":"39","author":"DM Kurtz","year":"2021","unstructured":"Kurtz, D. M. et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat. Biotechnol. 39, 1537\u20131547 (2021).","journal-title":"Nat. Biotechnol."},{"key":"6903_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809\u2013819 (2010).","journal-title":"N. Engl. J. Med."},{"key":"6903_CR7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","volume":"26","author":"A Lievre","year":"2008","unstructured":"Lievre, A. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374\u2013379 (2008).","journal-title":"J. Clin. Oncol."},{"key":"6903_CR8","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497\u20131500 (2004).","journal-title":"Science"},{"key":"6903_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561\u2013566 (2007).","journal-title":"Nature"},{"key":"6903_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503\u2013511 (2000).","journal-title":"Nature"},{"key":"6903_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679\u2013690 (2018).","journal-title":"Nat. Med."},{"key":"6903_CR12","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz, R. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 378, 1396\u20131407 (2018).","journal-title":"N. Engl. J. Med."},{"key":"6903_CR13","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon, S. P. et al. Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia. N. Engl. J. Med. 372, 1430\u20131440 (2015).","journal-title":"N. Engl. J. Med."},{"key":"6903_CR14","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","volume":"125","author":"J Reichel","year":"2015","unstructured":"Reichel, J. et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed\u2013Sternberg cells. Blood 125, 1061\u20131072 (2015).","journal-title":"Blood"},{"key":"6903_CR15","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","volume":"131","author":"E Tiacci","year":"2018","unstructured":"Tiacci, E. et al. Pervasive mutations of JAK\u2013STAT pathway genes in classical Hodgkin lymphoma. Blood 131, 2454\u20132465 (2018).","journal-title":"Blood"},{"key":"6903_CR16","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","volume":"3","author":"K Wienand","year":"2019","unstructured":"Wienand, K. et al. Genomic analyses of flow-sorted Hodgkin Reed\u2013Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv. 3, 4065\u20134080 (2019).","journal-title":"Blood Adv."},{"key":"6903_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1634\/theoncologist.2018-0058","volume":"24","author":"WS Liang","year":"2019","unstructured":"Liang, W. S. et al. Comprehensive genomic profiling of Hodgkin lymphoma reveals recurrently mutated genes and increased mutation burden. Oncologist 24, 219\u2013228 (2019).","journal-title":"Oncologist"},{"key":"6903_CR18","doi-asserted-by":"publisher","first-page":"111386","DOI":"10.18632\/oncotarget.22799","volume":"8","author":"E Mata","year":"2017","unstructured":"Mata, E. et al. Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets. Oncotarget 8, 111386\u2013111395 (2017).","journal-title":"Oncotarget"},{"key":"6903_CR19","doi-asserted-by":"crossref","unstructured":"Gomez, F. et al. Ultra-deep sequencing reveals the mutational landscape of classical Hodgkin lymphoma. Cancer Res. Commun. 3, 2312\u20132330 (2023).","DOI":"10.1158\/2767-9764.CRC-23-0140"},{"key":"6903_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1158\/2643-3230.BCD-22-0128","volume":"4","author":"F Maura","year":"2023","unstructured":"Maura, F. et al. Molecular evolution of classic Hodgkin lymphoma revealed through whole-genome sequencing of Hodgkin and Reed Sternberg cells. Blood Cancer Discov. 4, 208\u2013227 (2023).","journal-title":"Blood Cancer Discov."},{"key":"6903_CR21","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1182\/blood-2012-05-428896","volume":"120","author":"E Tiacci","year":"2012","unstructured":"Tiacci, E. et al. Analyzing primary Hodgkin and Reed\u2013Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood 120, 4609\u20134620 (2012).","journal-title":"Blood"},{"key":"6903_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.semcancer.2016.05.001","volume":"39","author":"MA Weniger","year":"2016","unstructured":"Weniger, M. A. & K\u00fcppers, R. NF-\u03baB deregulation in Hodgkin lymphoma. Semin. Cancer Biol. 39, 32\u201339 (2016).","journal-title":"Semin. Cancer Biol."},{"key":"6903_CR23","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.ccell.2022.10.022","volume":"40","author":"A Jamshidi","year":"2022","unstructured":"Jamshidi, A. et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell 40, 1537\u20131549.e12 (2022).","journal-title":"Cancer Cell"},{"key":"6903_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41587-022-01222-4","volume":"40","author":"MS Esfahani","year":"2022","unstructured":"Esfahani, M. S. et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nat. Biotechnol. 40, 585\u2013597 (2022).","journal-title":"Nat. Biotechnol."},{"key":"6903_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","volume":"16","author":"M Roschewski","year":"2015","unstructured":"Roschewski, M. et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 16, 541\u2013549 (2015).","journal-title":"Lancet Oncol."},{"key":"6903_CR26","doi-asserted-by":"publisher","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","volume":"8","author":"F Scherer","year":"2016","unstructured":"Scherer, F. et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci. Transl. Med. 8, 364ra155 (2016).","journal-title":"Sci. Transl. Med."},{"key":"6903_CR27","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","volume":"36","author":"DM Kurtz","year":"2018","unstructured":"Kurtz, D. M. et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J. Clin. Oncol. 36, 2845\u20132853 (2018).","journal-title":"J. Clin. Oncol."},{"key":"6903_CR28","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1200\/JCO.20.02573","volume":"39","author":"S Alig","year":"2021","unstructured":"Alig, S. et al. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma. J. Clin. Oncol. 39, 2605\u20132616 (2021).","journal-title":"J. Clin. Oncol."},{"key":"6903_CR29","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1182\/blood.2021012852","volume":"139","author":"L Meriranta","year":"2022","unstructured":"Meriranta, L. et al. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood 139, 1863\u20131877 (2022).","journal-title":"Blood"},{"key":"6903_CR30","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nbt.3520","volume":"34","author":"AM Newman","year":"2016","unstructured":"Newman, A. M. et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat. Biotechnol. 34, 547\u2013555 (2016).","journal-title":"Nat. Biotechnol."},{"key":"6903_CR31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","volume":"580","author":"JJ Chabon","year":"2020","unstructured":"Chabon, J. J. et al. Integrating genomic features for non-invasive early lung cancer detection. Nature 580, 245\u2013251 (2020).","journal-title":"Nature"},{"key":"6903_CR32","doi-asserted-by":"publisher","unstructured":"Sworder, B. J. et al. Determinants of resistance to engineered T-cell therapies targeting CD19 in large B-cell lymphomas. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2022.12.005 (2023).","DOI":"10.1016\/j.ccell.2022.12.005"},{"key":"6903_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ajhg.2020.01.008","volume":"106","author":"DSC Han","year":"2020","unstructured":"Han, D. S. C. et al. The biology of cell-free DNA fragmentation and the roles of DNASE1, DNASE1L3, and DFFB. Am. J. Hum. Genet. 106, 202\u2013214 (2020).","journal-title":"Am. J. Hum. Genet."},{"key":"6903_CR34","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1073\/pnas.1815031116","volume":"116","author":"L Serpas","year":"2019","unstructured":"Serpas, L. et al. Dnase1l3 deletion causes aberrations in length and end-motif frequencies in plasma DNA. Proc. Natl Acad. Sci. USA 116, 641\u2013649 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6903_CR35","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.bbrc.2019.06.069","volume":"516","author":"T Watanabe","year":"2019","unstructured":"Watanabe, T., Takada, S. & Mizuta, R. Cell-free DNA in blood circulation is generated by DNase1L3 and caspase-activated DNase. Biochem. Biophys. Res. Commun. 516, 790\u2013795 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"6903_CR36","first-page":"2343","volume":"141","author":"BJ Stewart","year":"2023","unstructured":"Stewart, B. J. et al. Spatial and molecular profiling of the mononuclear phagocyte network in classic Hodgkin lymphoma. Blood 141, 2343\u20132358 (2023).","journal-title":"Blood"},{"key":"6903_CR37","doi-asserted-by":"publisher","first-page":"e2200261","DOI":"10.1200\/PO.22.00261","volume":"6","author":"H Husain","year":"2022","unstructured":"Husain, H. et al. Tumor fraction correlates with detection of actionable variants across >23,000 circulating tumor DNA samples. JCO Precis. Oncol. 6, e2200261 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"6903_CR38","first-page":"993","volume":"3","author":"DM Blei","year":"2003","unstructured":"Blei, D. M., Ng, A. Y. & Jordan, M. I. Latent Dirichlet allocation. J. Mach. Learn. Res. 3, 993\u20131022 (2003).","journal-title":"J. Mach. Learn. Res."},{"key":"6903_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2020-141655","volume":"136","author":"ND Shukla","year":"2020","unstructured":"Shukla, N. D. et al. Profiling T-cell receptor diversity and dynamics during lymphoma immunotherapy using cell-free DNA (cfDNA). Blood 136, 49\u201350 (2020).","journal-title":"Blood"},{"key":"6903_CR40","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl, C. et al. Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N. Engl. J. Med. 362, 875\u2013885 (2010).","journal-title":"N. Engl. J. Med."},{"key":"6903_CR41","doi-asserted-by":"publisher","first-page":"pe55","DOI":"10.1126\/scisignal.1.51.pe55","volume":"1","author":"M Wills-Karp","year":"2008","unstructured":"Wills-Karp, M. & Finkelman, F. D. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci. Signal. 1, pe55 (2008).","journal-title":"Sci. Signal."},{"key":"6903_CR42","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1182\/blood-2017-09-808907","volume":"131","author":"E Vigano","year":"2018","unstructured":"Vigano, E. et al. Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK\u2013STAT signaling activation. Blood 131, 2036\u20132046 (2018).","journal-title":"Blood"},{"key":"6903_CR43","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1182\/blood.2020007683","volume":"138","author":"G Duns","year":"2021","unstructured":"Duns, G. et al. Characterization of DLBCL with a PMBL gene expression signature. Blood 138, 136\u2013148 (2021).","journal-title":"Blood"},{"key":"6903_CR44","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","volume":"99","author":"BF Skinnider","year":"2002","unstructured":"Skinnider, B. F. & Mak, T. W. The role of cytokines in classical Hodgkin lymphoma. Blood 99, 4283\u20134297 (2002).","journal-title":"Blood"},{"key":"6903_CR45","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.4049\/jimmunol.1201363","volume":"190","author":"S Rawal","year":"2013","unstructured":"Rawal, S. et al. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J. Immunol. 190, 6681\u20136693 (2013).","journal-title":"J. Immunol."},{"key":"6903_CR46","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1038\/leu.2010.223","volume":"24","author":"C Pangault","year":"2010","unstructured":"Pangault, C. et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent TFH\u2013B cell axis. Leukemia 24, 2080\u20132089 (2010).","journal-title":"Leukemia"},{"key":"6903_CR47","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1084\/jem.189.12.1939","volume":"189","author":"U Kapp","year":"1999","unstructured":"Kapp, U. et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed\u2013Sternberg cells. J. Exp. Med. 189, 1939\u20131946 (1999).","journal-title":"J. Exp. Med."},{"key":"6903_CR48","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ijc.28189","volume":"133","author":"A Natoli","year":"2013","unstructured":"Natoli, A. et al. Targeting the IL-4\/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs. Int. J. Cancer 133, 1945\u20131954 (2013).","journal-title":"Int. J. Cancer"},{"key":"6903_CR49","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000049523","volume":"126","author":"BF Skinnider","year":"2001","unstructured":"Skinnider, B. F., Kapp, U. & Mak, T. W. Interleukin 13: a growth factor in hodgkin lymphoma. Int. Arch. Allergy Immunol. 126, 267\u2013276 (2001).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"6903_CR50","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1182\/blood.V97.1.250","volume":"97","author":"BF Skinnider","year":"2001","unstructured":"Skinnider, B. F. et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed\u2013Sternberg cells of Hodgkin lymphoma. Blood 97, 250\u2013255 (2001).","journal-title":"Blood"},{"key":"6903_CR51","doi-asserted-by":"publisher","first-page":"8518","DOI":"10.1200\/JCO.2021.39.15_suppl.8518","volume":"39","author":"DM Kurtz","year":"2021","unstructured":"Kurtz, D. M. et al. Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer. J. Clin. Oncol. 39, 8518 (2021).","journal-title":"J. Clin. Oncol."},{"key":"6903_CR52","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1182\/bloodadvances.2020003039","volume":"5","author":"L Buedts","year":"2021","unstructured":"Buedts, L. et al. The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA. Blood Adv. 5, 1991\u20132002 (2021).","journal-title":"Blood Adv."},{"key":"6903_CR53","doi-asserted-by":"publisher","first-page":"103166","DOI":"10.1016\/j.critrevonc.2020.103166","volume":"157","author":"Z Hu","year":"2021","unstructured":"Hu, Z., Chen, H., Long, Y., Li, P. & Gu, Y. The main sources of circulating cell-free DNA: apoptosis, necrosis and active secretion. Crit. Rev. Oncol. Hematol. 157, 103166 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"6903_CR54","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1073\/pnas.1914949117","volume":"117","author":"STK Sin","year":"2020","unstructured":"Sin, S. T. K. et al. Identification and characterization of extrachromosomal circular DNA in maternal plasma. Proc. Natl Acad. Sci. USA 117, 1658\u20131665 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6903_CR55","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.2147\/OTT.S294332","volume":"14","author":"Z Deng","year":"2021","unstructured":"Deng, Z. et al. DNASE1L3 as a prognostic biomarker associated with immune cell infiltration in cancer. Onco Targets Ther. 14, 2003\u20132017 (2021).","journal-title":"Onco Targets Ther."},{"key":"6903_CR56","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3389\/fimmu.2017.00522","volume":"8","author":"G Shi","year":"2017","unstructured":"Shi, G., Abbott, K. N., Wu, W., Salter, R. D. & Keyel, P. A. Dnase1L3 regulates inflammasome-dependent cytokine secretion. Front. Immunol. 8, 522 (2017).","journal-title":"Front. Immunol."},{"key":"6903_CR57","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.cell.2017.06.046","volume":"170","author":"HY Chang","year":"2017","unstructured":"Chang, H. Y. & Nadeau, K. C. IL-4R\u03b1 inhibitor for atopic disease. Cell 170, 222 (2017).","journal-title":"Cell"},{"key":"6903_CR58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4329\/wjr.v9.i2.27","volume":"9","author":"M Bauckneht","year":"2017","unstructured":"Bauckneht, M., Piva, R., Sambuceti, G., Grossi, F. & Morbelli, S. Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography? World J. Radiol. 9, 27\u201333 (2017).","journal-title":"World J. Radiol."},{"key":"6903_CR59","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/jpm11030217","volume":"11","author":"C Ferrari","year":"2021","unstructured":"Ferrari, C. et al. Early evaluation of immunotherapy response in lymphoma patients by 18F-FDG PET\/CT: a literature overview. J. Pers. Med. 11, 217 (2021).","journal-title":"J. Pers. Med."},{"key":"6903_CR60","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","volume":"387","author":"SM Castellino","year":"2022","unstructured":"Castellino, S. M. et al. Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin\u2019s lymphoma. N. Engl. J. Med. 387, 1649\u20131660 (2022).","journal-title":"N. Engl. J. Med."},{"key":"6903_CR61","unstructured":"US Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03755804 (2023)."},{"key":"6903_CR62","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","volume":"20","author":"RO Casasnovas","year":"2019","unstructured":"Casasnovas, R. O. et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 20, 202\u2013215 (2019).","journal-title":"Lancet Oncol."},{"key":"6903_CR63","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.21.01281","volume":"41","author":"LM Fornecker","year":"2023","unstructured":"Fornecker, L. M. et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial. J. Clin. Oncol. 41, 327\u2013335 (2023).","journal-title":"J. Clin. Oncol."},{"key":"6903_CR64","first-page":"2576","volume":"141","author":"RC Lynch","year":"2023","unstructured":"Lynch, R. C. et al. Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma. Blood 141, 2576\u20132586 (2023).","journal-title":"Blood"},{"key":"6903_CR65","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1182\/blood-2019-129016","volume":"134","author":"H Ghesquieres","year":"2019","unstructured":"Ghesquieres, H. et al. Prednisone, vinblastine, doxorubicin and bendamustine (PVAB) regimen in first line therapy for older patients with advanced-stage classical Hodgkin lymphoma: results of a prospective multicenter phase II trial of the Lymphoma Study Association (LYSA). Blood 134, 2832 (2019).","journal-title":"Blood"},{"key":"6903_CR66","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548\u2013554 (2014).","journal-title":"Nat. Med."},{"key":"6903_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1114-x","volume":"17","author":"S Canisius","year":"2016","unstructured":"Canisius, S., Martens, J. W. & Wessels, L. F. A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence. Genome Biol. 17, 261 (2016).","journal-title":"Genome Biol."},{"key":"6903_CR68","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-19-0622","volume":"10","author":"P Jiang","year":"2020","unstructured":"Jiang, P. et al. Plasma DNA end-motif profiling as a fragmentomic marker in cancer, pregnancy, and transplantation. Cancer Discov. 10, 664\u2013673 (2020).","journal-title":"Cancer Discov."},{"key":"6903_CR69","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"6903_CR70","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"6903_CR71","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/nmeth.2646","volume":"10","author":"JP O\u2019Shea","year":"2013","unstructured":"O\u2019Shea, J. P. et al. pLogo: a probabilistic approach to visualizing sequence motifs. Nat. Methods 10, 1211\u20131212 (2013).","journal-title":"Nat. Methods"},{"key":"6903_CR72","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e29 (2021).","journal-title":"Cell"},{"key":"6903_CR73","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","volume":"10","author":"T Aoki","year":"2020","unstructured":"Aoki, T. et al. Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma. Cancer Discov. 10, 406\u2013421 (2020).","journal-title":"Cancer Discov."},{"key":"6903_CR74","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.3389\/fimmu.2019.02458","volume":"10","author":"I Sanz","year":"2019","unstructured":"Sanz, I. et al. Challenges and opportunities for consistent classification of human B cell and plasma cell populations. Front. Immunol. 10, 2458 (2019).","journal-title":"Front. Immunol."},{"key":"6903_CR75","doi-asserted-by":"publisher","first-page":"e20200483","DOI":"10.1084\/jem.20200483","volume":"217","author":"AB Holmes","year":"2020","unstructured":"Holmes, A. B. et al. Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome. J. Exp. Med. 217, e20200483 (2020).","journal-title":"J. Exp. Med."},{"key":"6903_CR76","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-021-00824-9","volume":"7","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Integrated single-cell RNA sequencing analysis reveals distinct cellular and transcriptional modules associated with survival in lung cancer. Signal Transduct. Target. Ther. 7, 9 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"6903_CR77","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"6903_CR78","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1101\/gr.234807.118","volume":"29","author":"JW Foley","year":"2019","unstructured":"Foley, J. W. et al. Gene expression profiling of single cells from archival tissue with laser-capture microdissection and Smart-3SEQ. Genome Res. 29, 1816\u20131825 (2019).","journal-title":"Genome Res."},{"key":"6903_CR79","doi-asserted-by":"crossref","unstructured":"Grossiord, E. et al. in 2015 IEEE 12th International Symposium on Biomedical Imaging (ISBI) 1118\u20131121 (IEEE, 2015).","DOI":"10.1109\/ISBI.2015.7164068"},{"key":"6903_CR80","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2967\/jnumed.118.211607","volume":"59","author":"R Boellaard","year":"2018","unstructured":"Boellaard, R. Quantitative oncology molecular analysis suite: ACCURATE. J. Nucl. Med. 59, 1753 (2018).","journal-title":"J. Nucl. Med."},{"key":"6903_CR81","doi-asserted-by":"publisher","first-page":"e105682","DOI":"10.1371\/journal.pone.0105682","volume":"9","author":"K Hirata","year":"2014","unstructured":"Hirata, K. et al. A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS ONE 9, e105682 (2014).","journal-title":"PLoS ONE"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06903-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06903-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06903-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T19:24:35Z","timestamp":1730834675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06903-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":81,"journal-issue":{"issue":"7996","published-print":{"date-parts":[[2024,1,25]]}},"alternative-id":["6903"],"URL":"https:\/\/doi.org\/10.1038\/s41586-023-06903-x","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"assertion":[{"value":"19 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K.A. reports speaker honoraria from Takeda. M.S.E. reports consultancy for Foresight Diagnostics. J.E.F. reports research funding from Seattle Genetics. B.J.S. reports consultancy for Foresight Diagnostics. A.S. is currently employed by Foresight Diagnostics. Y.N. reports consultancy for Roche & Leica Biosystems and research funding from Kite Pharma. D.R. reports consultancy, honoraria, research funding and travel support from AstraZeneca, Janssen, AbbVie, Gilead, MSD, BMS and BeiGene. R.L. reports research funding from TG Therapeutics, Incyte, Bayer, Cyteir, Genentech, SeaGen and Rapt, as well as consultancy for Cancer Study Group, SeaGen, Foresight Diagnostics and AbbVie. D.M.K. reports consultancy for Roche, Adaptive Biotechnologies and Genentech, equity ownership interest in Foresight Diagnostics, and patent filings, including patent issued, licensed and with royalties paid from Foresight. M.A. reports consultancy for Takeda, BMS, Karyopharm, Gilead and Incyte, research funding from Roche, Johnson & Johnson and Takeda, as well as travel support from Roche, BMS, Celgene, Gilead, AbbVie, AstraZeneca and Takeda. C.S. has performed consultancy for Bayer, and has received research funding from Epizyme and Trillium Therapeutics. M.D. reports research funding from AstraZeneca, Genentech, Varian Medical Systems and Illumina, ownership interest in CiberMed and Foresight Diagnostics, consultancy from AstraZeneca, Boehringer Ingelheim, BMS, Genentech, Gritstone Oncology, Illumina, Regeneron and Roche, and multiple issued and pending patents including patents licensed to Foresight Diagnostics and Roche. A.A.A. reports consultancy for Celgene, Chugai, Genentech, Gilead, Janssen, Pharmacyclics and Roche, scientific advisory board membership in the Lymphoma Research Foundation, and Professional Affiliations with the American Society of Hematology, American Society of Clinical Oncology, American Society of Clinical Investigation, Leukemia & Lymphoma Society, Research Funding from the National Cancer Institute, the National Heart, Lung, and Blood Institute, the US National Institutes of Health, Celgene, BMS and Pfizer, patent filings including patent issued, licensed and with royalties paid from FortySeven, a patent pending and Licensed to Foresight, a patent pending relating to MARIA, a patent issued and licensed to CiberMed, a patent issued and a patent pending to CiberMed, patents issued to Idiotype Vaccines, and a patent issued, licensed and with royalties paid from Roche, and equity ownership interests in CiberMed Inc., ForeSight Diagnostics, FortySeven Inc. and CARGO Therapeutics. S.K.A., M.S.E., M.Y.L., B.J.S., D.M.K., C.S., M.D. and A.A.A. also report patent filings related to cancer biomarkers. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}